News

Priyanka Baloni

Bile Acids Provide More Evidence of the Gut Microbiome’s Effect on Alzheimer’s Disease

ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.

Clinical Trial Explores the Effects of Health Coaching on Cognitive Function in Patients with Early-Stage Alzheimer’s

Institute for Systems Biology (ISB) is among several organizations conducting a clinical trial testing how health coaching affects the cognitive function of patients with early-stage Alzheimer’s disease and analyzing longitudinal, multi-omic data to explore transitions in cognitive function over time.

NIH-led effort – including ISB – launches Big Data portal for Alzheimer’s drug discovery

The National Institutes of Health announced the launch of a new Alzheimer’s Big Data portal, which includes the first wave of data for use by the research community. This portal is the result of the Accelerating Medicines Partnership (AMP) program, which focuses on facilitating collaboration among government agencies, academia and industry in order to translate research more quickly to therapies. The launch of the AMP Alzeheimers Disease Knowledge Portal is…